Grace Therapeutics, Inc. Receivables, Net, Current
Grace Therapeutics, Inc. (GRCE) had Receivables, Net, Current of $398.00 thousand as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:ReceivablesNetCurrent · last filed 2024-08-09
- 2024-06-30: Receivables, Net, Current $398.00K.
- 2024-03-31: Receivables, Net, Current $722.00K.
- 2023-12-31: Receivables, Net, Current $959.00K.
- 2023-09-30: Receivables, Net, Current $837.00K.
| Period end | Receivables, Net, Current |
|---|---|
| 2024-06-30 | $398.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $722.00K 10-Q · filed 2024-08-09 |
| 2023-12-31 | $959.00K 10-Q · filed 2024-02-12 |
| 2023-09-30 | $837.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $837.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $802.00K 10-K · filed 2024-06-21 |
| 2022-12-31 | $778.00K 10-Q · filed 2023-02-14 |
| 2022-09-30 | $859.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $964.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $548.00K 10-K · filed 2023-06-23 |
| 2021-12-31 | $238.00K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $813.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $448.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $530.00K 10-K · filed 2022-06-21 |
| 2020-12-31 | $619.00K 10-Q · filed 2021-02-09 |
| 2020-09-30 | $625.00K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $495.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $546.00K 10-K · filed 2021-06-22 |
| 2019-03-31 | $1.19M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |